Skip to main content


Cardiovascular Diabetology’s anniversary collection

New Content ItemFifteen years ago, professors Alexander Tenenbaum and Enrique Fisman conceived the idea of creating a scientific journal specifically dedicated to exploring the intersection of diabetes and heart disease. Following their initiative, the journal Cardiovascular Diabetology was launched in April 2002.

Since then, Cardiovascular Diabetology has been growing rapidly, and fortunately became a prestigious international journal that has published more than 1250 scientific articles - some of them representing a major breakthrough in their particular fields. The journal is privileged to have a high-status Editorial Board, a rigorous peer review policy, a multidisciplinary audience, high visibility, and ample global exposure.

April 2002 may also be considered as the official "birthday" of a novel medical area - cardiovascular diabetology - a discipline specifically dedicated to fight against cardio-diabetes and metabolism-related cardiovascular diseases.  On this occasion, Cardiovascular Diabetology would like to express its gratitude to the worldwide recognized scientists on its Editorial Board, the authors, the publisher’s staff, the reviewers and the readership for their continuous backing and assistance.

We are pleased to present the most influential manuscripts in cardiovascular diabetology published over our 15 year history and we look forward to the prolific studies the next 15 years will bring. We believe that the rapid progress of cardiovascular diabetology will lead to even more impressive achievements in both basic and clinical science, which will be reflected in improved public health.

The future looks encouraging.

  1. Original investigation

    Vascular endothelial microparticles-incorporated microRNAs are altered in patients with diabetes mellitus

    Circulating microRNAs (miRs) are differentially regulated and selectively packaged into microparticles (MPs). We evaluated whether diabetes mellitus alters circulating vascular and endothelial MP-incorporated ...

    Felix Jansen, Han Wang, David Przybilla, Bernardo S. Franklin, Andreas Dolf, Philipp Pfeifer, Theresa Schmitz, Anna Flender, Elmar Endl, Georg Nickenig and Nikos Werner

    Cardiovascular Diabetology 2016 15:49

    Published on: 22 March 2016

  2. Original investigation

    Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

    A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk w...

    Christian Sonesson, Peter A. Johansson, Eva Johnsson and Ingrid Gause-Nilsson

    Cardiovascular Diabetology 2016 15:37

    Published on: 19 February 2016

  3. Original investigation

    Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes

    Overweight or obesity contributes to the development of type 2 diabetes mellitus (T2DM) and increases cardiovascular risk. Exenatide, a glucagon-like peptide-1 receptor agonist, significantly reduces glycated ...

    Lawrence Blonde, Richard Pencek and Leigh MacConell

    Cardiovascular Diabetology 2015 14:12

    Published on: 3 February 2015

  4. Original investigation

    Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

    This study evaluated the effect of empagliflozin on postprandial glucose (PPG) and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus (T2DM).

    Rimei Nishimura, Yuko Tanaka, Kazuki Koiwai, Kohei Inoue, Thomas Hach, Afshin Salsali, Søren S Lund and Uli C Broedl

    Cardiovascular Diabetology 2015 14:11

    Published on: 30 January 2015

  5. Original investigation

    Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes

    Diabetes increases the risk of heart failure but the underlying mechanisms leading to diabetic cardiomyopathy are poorly understood. Left ventricle diastolic dysfunction (LVDD) is one of the earliest cardiac c...

    Ricardo Fontes-Carvalho, Ricardo Ladeiras-Lopes, Paulo Bettencourt, Adelino Leite-Moreira and Ana Azevedo

    Cardiovascular Diabetology 2015 14:4

    Published on: 13 January 2015

  6. Original investigation

    Antagonistic effect of TNF-alpha and insulin on uncoupling protein 2 (UCP-2) expression and vascular damage

    It has been reported that increased expression of UCP-2 in the vasculature may prevent the development of atherosclerosis in patients with increased production of reactive oxygen species, as in the diabetes, o...

    Almudena Gómez-Hernández, Liliana Perdomo, Natalia de las Heras, Nuria Beneit, Óscar Escribano, Yolanda F Otero, Carlos Guillén, Sabela Díaz-Castroverde, Beatriz Gozalbo-López, Victoria Cachofeiro, Vicente Lahera and Manuel Benito

    Cardiovascular Diabetology 2014 13:108

    Published on: 31 July 2014

  7. Study protocol

    Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

    Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV) outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely...

    Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, Roberto Ferrari, David Fitchett, Erich Bluhmki, Stefan Hantel, Joan Kempthorne-Rawson, Jennifer Newman, Odd Erik Johansen, Hans-Juergen Woerle and Uli C Broedl

    Cardiovascular Diabetology 2014 13:102

    Published on: 19 June 2014

  8. Original investigation

    Advanced glycation endproducts trigger autophagy in cadiomyocyte Via RAGE/PI3K/AKT/mTOR pathway

    Rat neonate cardiomyocytes were cultured and treated with AGEs at different concentration. Two classic autophagy markers, microtubule-associated protein 1 light chain 3 (LC3) and Beclin-1, were detected by wes...

    Xuwei Hou, Zhaohui Hu, Hanying Xu, Jian Xu, Shunrong Zhang, Yigang Zhong, Xiuying He and Ningfu Wang

    Cardiovascular Diabetology 2014 13:78

    Published on: 14 April 2014

  9. Original investigation

    The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

    Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial...

    David ZI Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten and Uli C Broedl

    Cardiovascular Diabetology 2014 13:28

    Published on: 29 January 2014

  10. Original investigation

    Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor

    Advanced glycation end products (AGEs) and receptor RAGE interaction play a role in diabetic vascular complications. Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potential therapeutic target for type 2 di...

    Yuji Ishibashi, Takanori Matsui, Sayaka Maeda, Yuichiro Higashimoto and Sho-ichi Yamagishi

    Cardiovascular Diabetology 2013 12:125

    Published on: 28 August 2013

  11. Original investigation

    Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

    This study investigated the cardiovascular (CV) safety profile of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin versus comparator treatments.

    Odd Erik Johansen, Dietmar Neubacher, Maximilian von Eynatten, Sanjay Patel and Hans-Juergen Woerle

    Cardiovascular Diabetology 2012 11:3

    Published on: 10 January 2012

  12. Original investigation

    Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

    It is important for patients that treatments for diabetes not increase cardiovascular (CV) risk. The objective of this analysis was to examine retrospectively the CV safety of exenatide BID, a GLP-1 receptor a...

    Robert Ratner, Jenny Han, Dawn Nicewarner, Irina Yushmanova, Byron J Hoogwerf and Larry Shen

    Cardiovascular Diabetology 2011 10:22

    Published on: 16 March 2011

  13. Original investigation

    Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study

    Our aim was to compare the effects of a Paleolithic ('Old Stone Age') diet and a diabetes diet as generally recommended on risk factors for cardiovascular disease in patients with type 2 diabetes not treated w...

    Tommy Jönsson, Yvonne Granfeldt, Bo Ahrén, Ulla-Carin Branell, Gunvor Pålsson, Anita Hansson, Margareta Söderström and Staffan Lindeberg

    Cardiovascular Diabetology 2009 8:35

    Published on: 16 July 2009

  14. Review

    Endothelial dysfunction: a comprehensive appraisal

    The endothelium is a thin monocelular layer that covers all the inner surface of the blood vessels, separating the circulating blood from the tissues. It is not an inactive organ, quite the opposite. It works ...

    Ricardo J Esper, Roberto A Nordaby, Jorge O Vilariño, Antonio Paragano, José L Cacharrón and Rogelio A Machado

    Cardiovascular Diabetology 2006 5:4

    Published on: 23 February 2006

  15. Original investigation

    Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease

    Inflammation contributes to cardiovascular disease and is exacerbated with increased adiposity, particularly omental adiposity; however, the role of epicardial fat is poorly understood.

    Adam R Baker, Nancy F da Silva, David W Quinn, Alison L Harte, Domenico Pagano, Robert S Bonser, Sudhesh Kumar and Philip G McTernan

    Cardiovascular Diabetology 2006 5:1

    Published on: 13 January 2006

  16. Review

    How hyperglycemia promotes atherosclerosis: molecular mechanisms

    Both type I and type II diabetes are powerful and independent risk factors for coronary artery disease (CAD), stroke, and peripheral arterial disease. Atherosclerosis accounts for virtually 80% of all deaths a...

    Doron Aronson and Elliot J Rayfield

    Cardiovascular Diabetology 2002 1:1

    Published on: 8 April 2002